Monopar Therapeutics Inc.

MNPR

US61023L1089

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-14 EDT			5-day change	1st Jan Change
0.94 ^USD	+2.81%		+15.91%	+176.31%

05-24	Monopar Therapeutics Names Karthik Radhakrishnan as CFO	MT
05-24	Monopar Therapeutics Inc. Announces CFO Changes	CI

Monopar Therapeutics Inc. Announces Termination of Employment of Kirsten Anderson, Senior Vice President of Clinical Development

July 02, 2018 at 02:00 pm

On June 20, 2018, Kirsten Anderson, the Senior Vice President of Clinical Development of Monopar Therapeutics Inc., upon mutual agreement was terminated from her employment with the Company.

Latest news about Monopar Therapeutics Inc.

Monopar Therapeutics Names Karthik Radhakrishnan as CFO	05-24	MT
Monopar Therapeutics Inc. Announces CFO Changes	05-24	CI
Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct	04-16	MT
Monopar Therapeutics Inc. Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings	04-16	CI
North American Morning Briefing : Big Banks Kick -2-	04-12	DJ
JonesTrading Upgrades Monopar Therapeutics to Buy From Hold, Price Target is $2	04-11	MT
Monopar Therapeutics Inc Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients	04-10	CI
Monopar Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Monopar Therapeutics Inc. Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program	03-05	CI
Sector Update: Health Care Stocks Gain Late Afternoon	02-22	MT
Sector Update: Health Care	02-22	MT
Monopar Therapeutics Shares Rise on 'Promising' Preclinical Cancer Treatment Trial Results	02-22	MT
Top Midday Gainers	02-22	MT
Monopar Therapeutics Inc. Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers	02-22	CI
Sector Update: Health Care Stocks Softer Tuesday Afternoon	02-20	MT
Monopar Therapeutics Gets Clearance to Start Phase 1 Trial in Advanced Cancers in Australia	02-20	MT
Monopar Receives Clearance to Proceed with First-In-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers	02-20	CI
Monopar Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Wall Street Set to Open Mixed Ahead of Federal Reserve Meeting	11-01	MT
Investors Await Fed Decision as US Futures Move Lower in Wednesday's Premarket Activity	11-01	MT
Top Premarket Gainers	11-01	MT
Monopar Therapeutics Inc. Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society Annual Meeting	11-01	CI
JonesTrading Downgrades Monopar Therapeutics to Hold From Buy	23-08-10	MT
Monopar Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI

Chart Monopar Therapeutics Inc.

Duration

Period

More charts

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.94 USD

Average target price

2.08 USD

Spread / Average Target

+121.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MONOPAR THERAPEUTICS INC.	+176.31%	16.44M
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.79%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research